Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935280 | 1.00 | CYP2D6 (0.50) | CYP2D6MBTD1L3MBTL3MC4RSLC6A2 | |
| SCHEMBL16935182 | 1.00 | CYP2D6 (0.50) | CYP2D6MBTD1L3MBTL3MC4RSLC6A2 | |
| SCHEMBL3041069 | 0.98 | CYP2D6 (0.52) | CYP2D6MBTD1L3MBTL3MC4RSLC6A2 | |
| SCHEMBL4248140 | 0.94 | CYP2D6 (0.52) | CYP2D6MBTD1L3MBTL3MC4RSLC6A2 | |
| SCHEMBL5553082 | 0.92 | CYP2D6 (0.47) | CYP2D6MBTD1L3MBTL3MC4RSLC6A2 | |
| SCHEMBL5549400 | 0.92 | CYP2D6 (0.47) | CYP2D6MBTD1L3MBTL3MC4RSLC6A2 | |
| SCHEMBL30206300 | 0.82 | MC4R (0.67) | CYP2D6MC4RSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL28327890 | 0.82 | MC4R (0.67) | CYP2D6MC4RSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL26199247 | 0.82 | MC4R (0.67) | CYP2D6MC4RSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL16982012 | 0.81 | CYP2D6 (0.56) | CYP2D6MC4ROPRM1LTA4HCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110506044-B | BRD4 inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-07-05 | — | — | CN | disclosed |
| CN-110506044-A | A kind of BRD4 inhibitor and its preparation and application | SHANGHAI INST MATERIA MEDICA CAS | 2019-11-26 | — | — | CN | disclosed |
| WO-2015110999-A1 | EZH2 INHIBITORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-07-30 | — | — | WO | disclosed |
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| CN-1263751-C | Novel compounds | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| CN-1541214-A | Novel compounds | — | 2004-10-27 | — | — | CN | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | CYP2D6 13/4885MBTD1 3425/4885L3MBTL3 4150/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | CYP2D6 14/4885MBTD1 2881/4885L3MBTL3 4553/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | CYP2D6 13/4885MBTD1 3425/4885L3MBTL3 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.